7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Satsuma Pharmaceuticals, Inc
(NASDAQ:STSA) 

STSA stock logo

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in AS...

Founded: 2016
IPO Price: $15 (Sep 13, 2019)
Full Time Employees: 17
CEO: John A. Kollins  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Satsuma Pharmaceuticals Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.48-2.13-1.77-1.42-1.06-0.71-0.350
Satsuma Pharmaceuticals Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.45-2.1-1.75-1.4-1.05-0.7-0.350
Satsuma Pharmaceuticals Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.310.620.921.231.541.852.16
Satsuma Pharmaceuticals (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -4.89-4.19-3.49-2.79-2.09-1.4-0.70
Satsuma Pharmaceuticals P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.440.871.311.752.182.623.06
No extra charts and metrics for this ticker.